Myeloma in Elderly Patients: When Less Is More and More Is More

Ashley Rosko, Sergio Giralt, Maria Victoria Mateos, Angela Dispenzieri

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.

Original languageEnglish (US)
Pages (from-to)575-585
Number of pages11
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Volume37
DOIs
StatePublished - Jan 1 2017

Fingerprint

Stem Cell Transplantation
Aptitude
Residual Neoplasm
Therapeutic Uses
Hematologic Neoplasms
Plasma Cells
Multiple Myeloma
Disease-Free Survival
Decision Making
Therapeutics
Quality of Life
Survival
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Myeloma in Elderly Patients : When Less Is More and More Is More. / Rosko, Ashley; Giralt, Sergio; Mateos, Maria Victoria; Dispenzieri, Angela.

In: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, Vol. 37, 01.01.2017, p. 575-585.

Research output: Contribution to journalReview article

@article{fdcffca6d6914199ae510adf33b84802,
title = "Myeloma in Elderly Patients: When Less Is More and More Is More",
abstract = "Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15{\%} of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.",
author = "Ashley Rosko and Sergio Giralt and Mateos, {Maria Victoria} and Angela Dispenzieri",
year = "2017",
month = "1",
day = "1",
doi = "10.14694/EDBK_175171",
language = "English (US)",
volume = "37",
pages = "575--585",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Myeloma in Elderly Patients

T2 - When Less Is More and More Is More

AU - Rosko, Ashley

AU - Giralt, Sergio

AU - Mateos, Maria Victoria

AU - Dispenzieri, Angela

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.

AB - Multiple myeloma is a plasma cell malignancy that occurs among older adults and accounts for 15% of all hematologic malignancies in the United States. Thirty-five percent of patients are diagnosed at age 75 or older. Novel therapeutics and routine use of autologous stem cell transplantation (ASCT) have led to substantial improvements in patient survival, although improvements have been more impressive among patients younger than age 65. Finding the balance between under- and overtreating elderly patients is one of the biggest challenges specific to them as a subgroup of patients with MM. Decision making about which therapies and their dose intensity and duration should be influenced by a patient's functional status, personal preferences, disease characteristics, and ability to tolerate therapy. ASCT should be considered for all patients younger than age 80, assuming that they are not frail. The attainment of a stringent complete response and minimal residual disease negativity is associated with improved progression-free and overall survival. Again, consideration of quality of life for these patients is paramount. Although there is a growing list of tools to sort through these issues, a fully integrated approach has not yet been finely tuned, leaving additional work to be done for the treatment of elderly patients with MM.

UR - http://www.scopus.com/inward/record.url?scp=85042257982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042257982&partnerID=8YFLogxK

U2 - 10.14694/EDBK_175171

DO - 10.14694/EDBK_175171

M3 - Review article

C2 - 28561667

AN - SCOPUS:85042257982

VL - 37

SP - 575

EP - 585

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

ER -